Patents by Inventor Ann Lovgren

Ann Lovgren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9433664
    Abstract: The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: September 6, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ann Lovgren, Kenny Hansson
  • Publication number: 20090047273
    Abstract: The present invention relates to a method is provided for producing recombinant human thrombin from recombinant prothrombin using recombinant ecarin having the sequence SEQ ID NO 2 or a homologue thereof.
    Type: Application
    Filed: July 3, 2008
    Publication date: February 19, 2009
    Inventors: Anna Harrysson, Ann Lovgren
  • Publication number: 20080312127
    Abstract: The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a ?-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields.
    Type: Application
    Filed: April 10, 2006
    Publication date: December 18, 2008
    Inventor: Ann Lovgren
  • Publication number: 20050164367
    Abstract: The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ?-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.
    Type: Application
    Filed: October 14, 2004
    Publication date: July 28, 2005
    Applicant: AstraZeneca AB
    Inventors: Christel Fenge, Ann Lovgren, Anders Thelin